Cargando…
Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis
BACKGROUND AND AIM: Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD). Till now, few papers regarding on-treatment hepatic decompensation have been reported. The study aims to analyze the general...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107263/ https://www.ncbi.nlm.nih.gov/pubmed/30138456 http://dx.doi.org/10.1371/journal.pone.0202777 |
_version_ | 1783349947969568768 |
---|---|
author | Hsieh, Yi-Chung Jeng, Wen-Juei Huang, Chien-Hao Teng, Wei Chen, Wei-Ting Chen, Yi-Cheng Lin, Shi-Ming Tai, Dar-In Lin, Chun-Yen Sheen, I-Shyan |
author_facet | Hsieh, Yi-Chung Jeng, Wen-Juei Huang, Chien-Hao Teng, Wei Chen, Wei-Ting Chen, Yi-Cheng Lin, Shi-Ming Tai, Dar-In Lin, Chun-Yen Sheen, I-Shyan |
author_sort | Hsieh, Yi-Chung |
collection | PubMed |
description | BACKGROUND AND AIM: Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD). Till now, few papers regarding on-treatment hepatic decompensation have been reported. The study aims to analyze the general feature and predictive factors of on-treatment hepatic decompensation in hepatitis C virus (HCV) genotype 1b-infected patients with advanced fibrosis and compensated cirrhosis who receive treatment with PrOD. METHODS: A real-word cohort enrolled 189 HCV genotype 1b patients with advanced fibrosis and compensated cirrhosis treated with 12-week PrOD. Clinical and laboratory data were analyzed between patients with and without on-treatment hepatic decompensation. RESULTS: The sustained virologic response rate at 12 weeks after treatment was 97.3% in HCV subtype 1b patients with advanced fibrosis and cirrhosis. On-treatment hyperbilirubinemia (total bilirubin >2 mg/dL) occurred in 27 (14.3%) patients, and the incidence of the increase of total and direct form bilirubin was significantly different during treatment between patients with Child-Turcotte-Pugh score 5 and score 6. Five (18.5%) hyperbilirubinemia patients progressed to hepatic decompensation. Older age (adjusted OR: 1.2, 95% CI: 1.0–1.4) and albumin ≤3.6 g/dL (adjusted OR: 10.4, 95% CI: 1.3–81.2) may be two predictors for on-treatment hepatic decompensation by multivariate analysis. CONCLUSIONS: PrOD is an effective direct-acting antiviral agent for antiviral therapy in HCV genotype 1b patients with advanced fibrosis and cirrhosis. Hyperbilirubinemia is possibly the early warning feature of on-treatment hepatic decompensation. This serious adverse event of on-treatment hepatic decompensation is not common. Older age and low baseline albumin level may be predictive factors. |
format | Online Article Text |
id | pubmed-6107263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-61072632018-08-30 Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis Hsieh, Yi-Chung Jeng, Wen-Juei Huang, Chien-Hao Teng, Wei Chen, Wei-Ting Chen, Yi-Cheng Lin, Shi-Ming Tai, Dar-In Lin, Chun-Yen Sheen, I-Shyan PLoS One Research Article BACKGROUND AND AIM: Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD). Till now, few papers regarding on-treatment hepatic decompensation have been reported. The study aims to analyze the general feature and predictive factors of on-treatment hepatic decompensation in hepatitis C virus (HCV) genotype 1b-infected patients with advanced fibrosis and compensated cirrhosis who receive treatment with PrOD. METHODS: A real-word cohort enrolled 189 HCV genotype 1b patients with advanced fibrosis and compensated cirrhosis treated with 12-week PrOD. Clinical and laboratory data were analyzed between patients with and without on-treatment hepatic decompensation. RESULTS: The sustained virologic response rate at 12 weeks after treatment was 97.3% in HCV subtype 1b patients with advanced fibrosis and cirrhosis. On-treatment hyperbilirubinemia (total bilirubin >2 mg/dL) occurred in 27 (14.3%) patients, and the incidence of the increase of total and direct form bilirubin was significantly different during treatment between patients with Child-Turcotte-Pugh score 5 and score 6. Five (18.5%) hyperbilirubinemia patients progressed to hepatic decompensation. Older age (adjusted OR: 1.2, 95% CI: 1.0–1.4) and albumin ≤3.6 g/dL (adjusted OR: 10.4, 95% CI: 1.3–81.2) may be two predictors for on-treatment hepatic decompensation by multivariate analysis. CONCLUSIONS: PrOD is an effective direct-acting antiviral agent for antiviral therapy in HCV genotype 1b patients with advanced fibrosis and cirrhosis. Hyperbilirubinemia is possibly the early warning feature of on-treatment hepatic decompensation. This serious adverse event of on-treatment hepatic decompensation is not common. Older age and low baseline albumin level may be predictive factors. Public Library of Science 2018-08-23 /pmc/articles/PMC6107263/ /pubmed/30138456 http://dx.doi.org/10.1371/journal.pone.0202777 Text en © 2018 Hsieh et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hsieh, Yi-Chung Jeng, Wen-Juei Huang, Chien-Hao Teng, Wei Chen, Wei-Ting Chen, Yi-Cheng Lin, Shi-Ming Tai, Dar-In Lin, Chun-Yen Sheen, I-Shyan Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis |
title | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis |
title_full | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis |
title_fullStr | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis |
title_full_unstemmed | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis |
title_short | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis |
title_sort | hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis c patients with advanced fibrosis and compensated cirrhosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107263/ https://www.ncbi.nlm.nih.gov/pubmed/30138456 http://dx.doi.org/10.1371/journal.pone.0202777 |
work_keys_str_mv | AT hsiehyichung hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis AT jengwenjuei hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis AT huangchienhao hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis AT tengwei hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis AT chenweiting hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis AT chenyicheng hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis AT linshiming hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis AT taidarin hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis AT linchunyen hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis AT sheenishyan hepaticdecompensationduringparitaprevirritonavirombitasvirdasabuvirtreatmentforgenotype1bchronichepatitiscpatientswithadvancedfibrosisandcompensatedcirrhosis |